JOP20190218A1 - مركبات ثنائية النيوكليوتيدات حلقية معدلة - Google Patents

مركبات ثنائية النيوكليوتيدات حلقية معدلة

Info

Publication number
JOP20190218A1
JOP20190218A1 JOP/2019/0218A JOP20190218A JOP20190218A1 JO P20190218 A1 JOP20190218 A1 JO P20190218A1 JO P20190218 A JOP20190218 A JO P20190218A JO P20190218 A1 JOP20190218 A1 JO P20190218A1
Authority
JO
Jordan
Prior art keywords
cyclic dinucleotide
modified cyclic
dinucleotide compounds
compounds
modified
Prior art date
Application number
JOP/2019/0218A
Other languages
English (en)
Inventor
Christian Andreas Kuttruff
Sebastian Carotta
Thorsten Oost
Martin Fleck
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20190218A1 publication Critical patent/JOP20190218A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

مركبات الصيغة (I) حيث يتم تعريف القاعدة 1 والقاعدة 2 بكما في عنصر الحماية 1 بأنهم معدلات STING.
JOP/2019/0218A 2017-03-22 2017-06-16 مركبات ثنائية النيوكليوتيدات حلقية معدلة JOP20190218A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17162392 2017-03-22

Publications (1)

Publication Number Publication Date
JOP20190218A1 true JOP20190218A1 (ar) 2019-09-22

Family

ID=58412904

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0218A JOP20190218A1 (ar) 2017-03-22 2017-06-16 مركبات ثنائية النيوكليوتيدات حلقية معدلة

Country Status (20)

Country Link
US (1) US10392419B2 (ar)
EP (1) EP3601313B1 (ar)
JP (2) JP6742534B2 (ar)
KR (1) KR20190130612A (ar)
CN (1) CN110382515B (ar)
AR (1) AR111247A1 (ar)
AU (1) AU2018239468A1 (ar)
BR (1) BR112019017812A2 (ar)
CA (1) CA3056008A1 (ar)
CL (1) CL2019002590A1 (ar)
CO (1) CO2019010023A2 (ar)
EA (1) EA201992209A1 (ar)
IL (1) IL268799A (ar)
JO (1) JOP20190218A1 (ar)
MX (1) MX2019011281A (ar)
PE (1) PE20191556A1 (ar)
PH (1) PH12019502155A1 (ar)
SG (1) SG11201908567UA (ar)
TW (1) TW201842919A (ar)
WO (1) WO2018172206A1 (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221263T1 (hr) 2016-03-18 2023-03-03 Immune Sensor, Llc Ciklički di-nukleotidni spojevi i postupci uporabe
WO2017223258A1 (en) * 2016-06-24 2017-12-28 Biogen Ma Inc. Synthesis of thiolated oligonucleotides without a capping step
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
PE20210156A1 (es) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111989338A (zh) * 2018-03-27 2020-11-24 勃林格殷格翰国际有限公司 修饰的环二核苷酸化合物
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチド
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
EP3891166A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
US20220033431A1 (en) * 2018-12-07 2022-02-03 Merck Sharp & Dohme Corp. Cyclic Di-Nucleotide Compounds as STING Agonists
EP3891165A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2022531899A (ja) 2019-05-09 2022-07-12 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
KR20220006519A (ko) 2019-05-10 2022-01-17 다케다 야쿠힌 고교 가부시키가이샤 항체 약물 접합체
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
AU2020362115A1 (en) * 2019-10-07 2022-04-21 The General Hospital Corporation Compositions and methods for pulmonary surfactant-biomimetic nanoparticles
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JP2023545178A (ja) 2020-10-14 2023-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ
PE20231947A1 (es) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US7709458B2 (en) 2004-03-15 2010-05-04 David K. R. Karaolis Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP2591001B1 (en) 2010-07-09 2021-11-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to cd27
SG11201502796RA (en) * 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
PL2934598T3 (pl) 2012-12-19 2018-10-31 Board Of Regents, The University Of Texas System Środek farmaceutyczny ukierunkowany na ssaczy szlak przekazywania sygnału przez cykliczne dinukleotydy
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
US9724408B2 (en) 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PT3116909T (pt) 2014-03-14 2020-01-30 Novartis Ag Moléculas de anticorpos para lag-3 e suas utilizações
SG11201609021QA (en) 2014-06-04 2016-11-29 Glaxosmithkline Ip Dev Ltd Cyclic di-nucleotides as modulators of sting
EP3546473A1 (en) 2014-12-16 2019-10-02 Kayla Therapeutics Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
CN107530415A (zh) * 2015-03-10 2018-01-02 艾杜罗生物科技公司 用于活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
KR102271750B1 (ko) 2015-08-13 2021-06-30 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
US11098077B2 (en) * 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة

Also Published As

Publication number Publication date
EA201992209A1 (ru) 2020-03-16
KR20190130612A (ko) 2019-11-22
EP3601313B1 (en) 2021-03-10
JP2020514389A (ja) 2020-05-21
CN110382515A (zh) 2019-10-25
US20180273578A1 (en) 2018-09-27
US10392419B2 (en) 2019-08-27
CO2019010023A2 (es) 2019-09-30
TW201842919A (zh) 2018-12-16
PE20191556A1 (es) 2019-10-24
AR111247A1 (es) 2019-06-19
IL268799A (en) 2019-10-31
SG11201908567UA (en) 2019-10-30
BR112019017812A2 (pt) 2020-03-31
MX2019011281A (es) 2019-11-01
JP2020203887A (ja) 2020-12-24
AU2018239468A1 (en) 2019-09-12
CN110382515B (zh) 2023-03-03
PH12019502155A1 (en) 2020-07-06
EP3601313A1 (en) 2020-02-05
CA3056008A1 (en) 2018-09-27
WO2018172206A1 (en) 2018-09-27
CL2019002590A1 (es) 2020-01-24
JP6742534B2 (ja) 2020-08-19

Similar Documents

Publication Publication Date Title
PH12019502155A1 (en) Modified cyclic dinucleotide compounds
PH12019500706A1 (en) Cyclic dinucleotide compounds
PH12019502870A1 (en) Small molecule modulators of human sting
ZA201805009B (en) Stable inoculant compositions and methods for producing same
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
ZA201507627B (en) P2x7 modulators
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
GB2547402A (en) Prevention and treatment of microbial infections
MX2019014041A (es) Inhibidores pirazolicos de magl.
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2017010357A (es) Derivados novedosos de n-acil-arilsulfonamida como inhibidores de aminoacil acido ribonucleico de transferencia (arnt) sintetasa.
WO2018237010A3 (en) VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
MX2022007179A (es) Compuestos heterociclicos funcionalizados como moduladores del estimulador de genes de interferon.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
MX2016012314A (es) Analagos de apelina ciclicos.
PH12018501585B1 (en) Novel pyrrolidine derivatives
WO2018022844A3 (en) COMPOSITIONS AND METHODS FOR MODULATION OF FACTOR IX FUNCTION
MX2020010159A (es) Composiciones de creatina y/o creatinina y metodos relacionados.
WO2019028012A3 (en) METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
MY173966A (en) A cell-based composition and use thereof for treatment of acute stroke
MY171690A (en) A cell-based composition and use thereof for treatment of end-stage ischemic cardiomyopathy
MY176109A (en) A cell-based composition and use thereof for treatment of critical limb ischemia